Table I.
Clinical characteristics of the patient population in the discovery and replication cohorts.
| Discovery cohort | Internal validation cohort | External validation cohort |
P-value |
||
|---|---|---|---|---|---|
| (n = 655) | (n = 457) | (n = 321) | Discovery vs internal validation cohort | Discovery vs external validation cohort | |
| median | median | median | |||
| (mean ± SEM) | (mean ± SEM) | (mean ± SEM) | |||
| Age, years | 28.9 | 28.6 | 28.0 | 0.61 | 0.01 |
| (28.8 ± 0.19) | (28.7 ± 0.21) | (28.0 ± 0.26) | |||
| BMI, kg/m2 | 24.4 | 23.7 | 35.5 | 0.12 | 2.2 × 10−16 |
| (26.0 ± 0.23) | (25.5 ± 0.28) | (35.7 ± 0.47) | |||
| AMH, ng/ml | 8.17 | 8.42 | 10.7 | 0.88 | 3.41 × 10−5 |
| (9.82 ± 0.27) | (9.45 ± 0.27) | (12.1 ± 0.45) | |||
| Total follicle count, n | 37.0 | 39.0 | – | 0.03 | – |
| (42.3 ± 0.84) | (45.0 ± 1.03) | ||||
| Testosterone, pmol/l | 1.70 | 1.34 | – | 8.97 × 10−12 | – |
| (1.86 ± 0.03) | (1.53 ± 0.04) | ||||
| FSH | 5.80 | 5.70 | – | 0.85 | – |
| (5.83 ± 0.10) | (5.89 ± 0.13) | ||||
| LH | 7.90 | 7.00 | – | 0.06 | – |
| (9.76 ± 0.34) | (9.55 ± 0.49) | ||||
| Ovulatory dysfunction, n (%) | 647 (98.8%) | 446 (97.6%) | 321 (100%) | 0.21 | – |
| Hyperandrogenism, n (%) | 337 (52.4%) | 221 (48.5%) | 321 (100%) | 0.34 | – |
| Polycystic ovaries, n (%) | 631 (96.3%) | 452 (98.9%) | – | 0.01 | – |
AMH, anti-Müllerian hormone. Values are expressed as median (mean ± SEM) or as percentages. AMH, testosterone, follicle count, FSH and LH levels were age-adjusted. P-values were obtained by performing the Mann–Whitney U test.